PTO/SB/08a (08-08)

INFORMATION DISCLOSUR
STATEMENT BY APPLICAN
( Not for submission under 37 CFR 1.99

Application Number		10045674	
Filing Date		2001-10-25	
First Named Inventor	Robert Ladner et al.		
Art Unit		1639	
Examiner Name	Jon D. Epperson		
Attorney Docket Number		D2033-708931	

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	Name of Pate of cited Docu	entee or Applicant Iment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1									
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	9906834	wo			1999-02-11	IXSYS Incorporate	d		
	2	9708320	wo			1997-03-06	Morphosys Gesells	chaft		
	3	0179481	wo		A2	2001-10-25	Dyax Corp.			

**U.S.PATENTS** 

/Christian Boesen/

08/23/2010

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10045674		
iling Date		2001-10-25		
irst Named Inventor	Robei	rt Ladner et al.		
Art Unit		1639		
xaminer Name	Jon D	. Epperson		
Morney Docket Number		D2033-708931		

		NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1	AUJAME et al., "High affinity human antibodies by phage display", Human Antibodies, 8(4):155-168 (1997).						
	2	BARBAS et al., "Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem," Proceedings of the National Academy of Sciences of USA, 89:4457-4461 (1992).						
	3	BALINT et al., "Antibody engineering by parsimonious mutagenesis," Gene, 1993, Vol. 137, pp. 109-118.						
	4	CORBETT et al., "Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination", J. Mol. Biol. 270(4): 587-597 (1997).						
	5	HOOGENBOOM et al., "Antibody phage display technology and its applications," Immunotechnology, 4(1):1-20 (1998).						
	6	JIRHOLT et al., "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," Gene, 1998, Vol. 215, No. 2, pp. 471-476.						
	7	KNAPPIK et al., "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleolides", J. Mol. Biol., 296:57-86 (2000).						
	8	KRUIF et al., "Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions", J. Mol. Biol., 248(1):97-105 (1995).						
	9	POWELL et al., "Construction, assembly and selection of combinatorial antibody libraries", pp. 155-172 in Genetic Engineering with PCR (Horton and Tait, Eds. 1998), Vol. 5 of The Current Innovations in Molecular Biology series, Horizon Scientific Press.						

/Christian Boesen/

08/23/2010

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

10045674

D2033-708931

	10	RYU et al., "Recent Progress in Biomolecular Engineering", Biotechi	nology Progress, 2000, V	ol. 15, No. 1, pp. 2-16.				
	11	SAVIRANTA et al., "Engineering the steroid-specificity of an anti-17 competitive phage panning," Protein Engineering, 1998, Vol. 11, No.		n mutagenesis and				
	12	SHEETS et al., "Efficient construction of a large nonimmune phage human single-chain antibodies to protein antigens," Proc. Natl. Acad			0			
	13	SHORT et al., "Contribution of Antibody Heavy Chain CDR1 to Digoxin Binding Analyzed by Random Mutagenesis of Phage-displayed Fab 26-10", Journal of Biol. Chem., Vol. 270 (1):28541-28550 (1995).						
	14	SODERLIND et al., "Domain libraries: Synthetic diversity for de novo design of antibody V-regions", Gene, 1995, Vol. 160, No. 2, pp. 269-272.						
	15	ZUCCONI et al., "Domain repertoires as a tool to derive protein recognition rules", 2000, FEBS Letters, Vol. 480, No. 1, pp. 49-54.						
If you wis	h to a	dd additional non-patent literature document citation informatio	please click the Add	button				
		EXAMINER SIGNATURE						
Examine	r Signa	ature /Christian Boesen/	Date Considered	08/23/2010				

Application Number

Attorney Docket Number

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.